Using engineered nanoparticles to reduce inflammation and scarring after heart attacks
Engineered nanoparticles to control inflammation and fibrosis after acute myocardial infarction
This study is exploring a new way to help your heart heal after a heart attack by using tiny particles to deliver medicine that reduces inflammation right where it's needed, which could improve your recovery and heart function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11063270 on NIH RePORTER |
What this research studies
This research investigates a novel approach to improve heart recovery after a heart attack by using engineered nanoparticles to deliver anti-inflammatory agents directly to the affected area. The goal is to transition the body's inflammatory response from a harmful phase to a healing phase more effectively. By targeting specific inflammatory signals and inhibiting the formation of scar tissue, this method aims to enhance cardiac function and repair. Patients who have experienced a heart attack may benefit from this innovative treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently suffered an acute myocardial infarction.
Not a fit: Patients who have not experienced a heart attack or those with advanced heart disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved recovery and heart function for patients after a heart attack.
How similar studies have performed: Other research has shown promise in using targeted delivery systems for anti-inflammatory therapies, suggesting potential success for this novel approach.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Guan, Jianjun — Washington University
- Study coordinator: Guan, Jianjun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.